The Tuberculosis Network European Trials group (TBnet) ERS Clinical Research Collaboration: addressing drug-resistant tuberculosis through European cooperation

While the incidence of tuberculosis (TB) has fallen steadily within the European Union, the region has by far the highest estimated incidence of multidrug-resistant (MDR)-TB among TB patients [1, 2], which hampers the goal of the World Health Organization (WHO) of TB elimination in the region [3]. MDR-TB has the potential to be the most important infectious threat to European health over the coming decades, unless effective treatment can be found and relapses prevented. The Tuberculosis Network European Trials group (TBnet) continues the successful ERS Clinical Research Collaboration on drug-resistant tuberculosis <http://ow.ly/gGH330mHrDa>